3 Indian Export Stocks That Could Gain From New Zealand Tariff Free Trade

A once theoretical trade link between India and New Zealand is about to become real money, as an imminent FTA strips tariffs to zero on all Indian goods landing in Kiwi ports. That shift could reshape profit pools for exporters, and investors who ignore it may miss a fresh source of earnings power. This article walks through three India listed industrials and healthcare suppliers that appear especially exposed to this new trade corridor.

The three stocks highlighted below are a starting sample, and the same export oriented screen surfaced 34 more Indian industrials and healthcare suppliers with equally compelling narratives that are not covered in this article.

If you want to identify and analyze the potential winners from this new trade link, head straight to the India Export-Oriented Industrials & Healthcare Suppliers to New Zealand screener.

Alivus Life Sciences (NSEI:ALIVUS)

Overview: Alivus Life Sciences develops and supplies active pharmaceutical ingredients and contract manufacturing services for multiple therapies to regulated markets worldwide.

Operations: Alivus Life Sciences generates its entire ₹25,904 million revenue from its Active Pharmaceutical Ingredient segment, reflecting a focused API business model.

Market Cap: ₹175.6 billion

Alivus Life Sciences fits this export oriented screen because it already ships complex APIs into major overseas markets. A tariff free entry point into New Zealand could extend an existing playbook rather than require a new one.

"Expansion of capacity at Solapur, Ankleshwar and Dahej, including continuous manufacturing and backward integration, positions Alivus to capture rising global API demand, supporting higher revenue growth and operating leverage driven improvement in EBITDA margins."

What happens to that margin story depends on how one unseen pressure on future export pricing and product mix eventually resolves.

That pricing pressure is the real hinge, and the full narrative for Alivus Life Sciences shows how Alivus Life Sciences could still accelerate earnings power if the export mix shifts in its favor.

IOL Chemicals and Pharmaceuticals (BSE:524164)

Overview: IOL Chemicals and Pharmaceuticals is an integrated manufacturer of active pharmaceutical ingredients and specialty chemicals that supplies export driven end markets worldwide.

Operations: IOL Chemicals and Pharmaceuticals generates about ₹15.4b from Pharmaceuticals and ₹12.4b from Chemicals, with internal inter segment sales of roughly ₹2.6b.

Market Cap: ₹59.6b

IOL Chemicals and Pharmaceuticals fits this export focused screen because it already ships both APIs and chemical intermediates into regulated markets where tariff cuts can matter. The India New Zealand FTA simply widens an existing channel for its mix of healthcare and industrial products.

"Rapidly increasing exports to regulated and international markets (targeting a rise from 25% to 40% of revenue in two years) position IOL to benefit from global demographic changes and increased healthcare spending, supporting robust long-term revenue growth."

What happens to that export story ultimately rests on how one unresolved pressure around product concentration and pricing power shapes margins in the next leg.

That concentration risk is exactly what the full narrative for IOL Chemicals and Pharmaceuticals unpacks, showing where IOL Chemicals and Pharmaceuticals could see pricing power accelerate or quietly stall next.

Granules India (BSE:532482)

Overview: Granules India manufactures and exports bulk drug ingredients, intermediates and finished tablets and capsules across a wide range of therapies.

Operations: Granules India generates about ₹56.3b in revenue from pharmaceutical products, reflecting a tightly focused core medicines portfolio.

Market Cap: ₹216.8b

Granules India sits squarely in this export oriented pharma group, and its mix of APIs and finished dosages makes it a cleaner way to play Indian formulations flowing into tariff free New Zealand.

"Expansion of in-house manufacturing, especially in peptides (dual-site in Switzerland and India), and backward integration initiatives enhance cost competitiveness and capacity utilization, expected to support sustainable gross margin improvements and earnings resilience."

What happens to that margin story depends on how one future shift in product mix and export pricing power ultimately plays out.

That next shift is exactly what the full narrative for Granules India unpacks, explaining how Granules India could see export earnings move independently from input costs while key risks remain contained.

Seeking Alternatives Before The Crowd

Fresh ideas move first, and slower money usually gets caught chasing momentum while early entries are already flying. Scan these under the radar lists while it matters and get in early.

• Spot cash generative operators before wider attention catches on by running the list of solid balance sheet and fundamentals (197 results) and filter for businesses where financial resilience backs every growth story.
• Target durable income streams while yields are still holding up by scanning the 155 dividend fortresses for companies built to keep paying when others cut.
• Ride the build out of next generation infrastructure by checking the 89 AI infrastructure stocks for operators supplying the picks and shovels behind AI demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com